Renishaw Diagnostics Ltd, formerly D3 Technologies Ltd, was a Strathclyde University spin-out before being acquired by the Renishaw Group, a leading global supplier of engineering technologies, medical devices and Raman spectroscopy systems. Renishaw Diagnostics is focused on developing and commercialising its first in vitro diagnostic (IVD) and clinical research products, with the goal of establishing Renishaw Diagnostics as the premium provider of automated, multiplex, high sensitivity molecular diagnostics products for the detection of human infectious diseases.
Renishaw Diagnostics uses novel patented technology based on Surface-Enhanced Resonance Raman Scattering (SERRS) to develop molecular diagnostic tests for the infectious disease market and for life & analytical science research applications. The main advantages of this new technology are high sensitivity, multiplex detection and analysis. The company sells specific Klarite® chemistry based detection methods for Surface-Enhanced Raman Scattering (SERS) for academic and industrial applications and is seeking commercial partners to further exploit the benefits of the technology for applications in biopharmaceutical clean up, biothreat and forensics.
Mission
Renishaw Diagnostics will provide automated, multiplex, high sensitivity molecular diagnostic systems to facilitate fast, reliable and simplified disease detection and thus enable clinicians to improve patient care.
